HAOHAI BIOTEC (06826) reported a net profit attributable to shareholders of approximately RMB 163 million for the first three quarters, a year-on-year decrease of 46.53%.
HAOHAI BIOTEC (06826) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 1.71 billion, a year-on-year decrease of 9.93%; net profit attributable to shareholders of the listed company of approximately RMB 163 million, a year-on-year decrease of 46.53%; and basic earnings per share of RMB 0.71.
HAOHAI BIOTEC (06826) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 1.71 billion, a year-on-year decrease of 9.93%; net profit attributable to shareholders of the listed company of approximately RMB 163 million, a year-on-year decrease of 46.53%; and basic earnings per share of RMB 0.71.
Related Articles
JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
DL HOLDINGS GP (01709) cancelled 2 million repurchased shares on October 23.
.png)
SIGENERGY (06656): Chen Liyan Appointed as Joint Company Secretary
JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
DL HOLDINGS GP (01709) cancelled 2 million repurchased shares on October 23.
SIGENERGY (06656): Chen Liyan Appointed as Joint Company Secretary
